文献速递前列腺癌

前列腺癌放疗后未达Phoenix生化复发标准前行前列腺特异性膜抗原正电子发射断层扫描:更早检出复发

Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences.
PubMed 文献 · Eur Urol Oncol · 2024-10-16

该回顾性分析纳入568例接受根治性放疗的前列腺癌患者,比较未达Phoenix标准(Ph-,222例)与达到标准(Ph+,346例)两组行PSMA PET/CT的检出率与疾病范围。Ph-组76.6%检出PSMA阳性病灶,局部挽救治疗机会更高(OR 3.84,p<0.001),远处转移更少(OR 0.29,p<0.001),至ADT再启动、CRPC进展时间更长且总死亡率更低。

要点

  • 未达Phoenix标准(Ph-)患者中76.6%经PSMA PET/CT检出复发病灶。
  • Ph-组局部挽救治疗机会高于Ph+组(OR 3.84,p<0.001)。
  • Ph-组远处转移比例低于Ph+组(21.8% vs 48.8%,OR 0.29)。

核心结论

  • 对于前列腺癌复发患者,PSMA PET/CT可在多数未达Phoenix生化复发标准者中检出复发。
  • 早期影像检查可在较不晚期阶段检出复发,并可能允许挽救性治疗。
  • 早期PSMA PET/CT与至ADT再启动、至CRPC进展时间更长及总生存更长相关。
  • 作者认为这些积极临床意义需在前瞻性研究中确认,以减少潜在领先时间偏倚。

研究设计与样本

  • 回顾性分析阿姆斯特丹前列腺癌网络(2015-2023)队列中568例接受根治性放疗的前列腺癌患者。
  • 收集PSMA PET/CT结果、治疗管理及临床随访数据,包括ADT(再)启动、CRPC进展和生存。
  • 采用逻辑回归和生存分析比较Ph-组与Ph+组。

主要发现

  • 队列中Ph-组222例(39.1%),Ph+组346例(60.9%)。
  • PSMA阳性病灶在Ph-组检出170例(76.6%),在Ph+组检出322例(93.1%)。
  • Ph-组75.9%适合局部挽救治疗,Ph+组45.0%适合局部挽救治疗(OR 3.84,p<0.001)。
  • 远处转移Ph-组37例(21.8%),Ph+组157例(48.8%;OR 0.29,p<0.001)。
  • 生存分析显示Ph-组至ADT(再)启动和至CRPC进展时间更长,总死亡率更低(log-rank p<0.001)。

关键数值与推荐

  • Phoenix生化复发标准定义为PSA较最低点升高≥2.0 ng/ml。
  • Ph-组适合局部挽救治疗比例75.9% vs Ph+组45.0%(OR 3.84,p<0.001)。
  • Ph-组远处转移21.8% vs Ph+组48.8%(OR 0.29,p<0.001)。
  • Ph-组至ADT(再)启动、至CRPC进展时间更长及总死亡率更低(log-rank p<0.001)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为早期PSMA PET/CT可在较不晚期阶段检出复发并可能允许挽救性治疗。
  • 作者认为早期PSMA PET/CT与至ADT再启动、至CRPC进展时间更长及总生存更长相关。

局限性

  • 回顾性研究设计是主要局限性。
  • 作者指出需在前瞻性研究中确认结果,以减少潜在领先时间偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Biochemical recurrence (BCR) of prostate cancer (PCa) after curative radiotherapy (RT) is defined according to the Phoenix criteria, which is a prostate-specific antigen (PSA) rise of ≥2.0 ng/ml above the PSA nadir. Prostate-specific membrane antigen (PSMA)-based positron emission tomography/computed tomography (PET/CT) can identify PCa recurrences at very low PSA values. Our aim was to investigate the detection rate and extent of PCa recurrences using PSMA PET/CT after curative RT among patients with a PSA rise of ≥2.0 ng/ml above the nadir (Phoenix positive, Ph+) and patients not reaching this threshold (Phoenix negative, Ph-) and to compare therapeutic management and clinical outcomes in terms of time to androgen deprivation therapy (ADT) and castration-resistance PCa (CRPC), as well as overall survival. METHODS: We conducted a retrospective analysis of the Prostate Cancer Network Amsterdam (2015-2023) cohort of 568 patients who received curative-intent RT for PCa. Data on PSMA PET/CT outcomes, therapeutic management, and clinical follow-up were collected, including (re)initiation of ADT, progression to CRPC, and survival. Results were compared between groups using logistic regression and survival analyses. KEY FINDINGS AND LIMITATIONS: The study cohort comprised 222 patients (39.1%) classified as Ph- and 346 (60.9%) classified as Ph+. PSMA-avid lesions were detected in 170 Ph- patients (76.6%) and 322 (93.1%) Ph+ patients. In these groups, 75.9% of Ph- patients and 45.0% of Ph+ patients were eligible for local salvage therapy (odds ratio [OR 3.84]; p < 0.001). Distant metastases were less frequent in the Ph- group (n = 37, 21.8%) than in the Ph+ group (n = 157, 48.8%; OR 0.29; p < 0.001). Survival analyses revealed longer times to ADT (re)initiation and progression to CRPC, as well as lower overall mortality, in the Ph- group (log-rank p < 0.001). The retrospective study design is the main limitation. CONCLUSIONS AND CLINICAL IMPLICATIONS: For patients with PCa recurrence, PSMA PET/CT can detect this recurrence in the majority of cases not meeting the Phoenix criteria for BCR. Early imaging detects recurrences at a less advanced disease stage, allowing potential salvage treatments. In addition, early PSMA PET/CT is associated with longer times to ADT (re)initiation and progression to CRPC, as well as longer overall survival. These positive clinical implications warrant confirmation of our results in prospective studies to reduce potential leadtime bias. PATIENT SUMMARY: We investigated early use of a special type of scan called PSMA PET (prostate-specific membrane antigen positron emission tomography) in patients with suspicion of recurrence of their prostate cancer after radiotherapy. Early scans can detect recurrence before the cancer progresses to a more advanced stage.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. van Altena EJE, Jansen BHE, Korbee ML, et al. Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences. Eur Urol Oncol. 2024. PMID: 39414419. doi:10.1016/j.euo.2024.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。